FI120397B - Nya sulfonamider - Google Patents
Nya sulfonamider Download PDFInfo
- Publication number
- FI120397B FI120397B FI972628A FI972628A FI120397B FI 120397 B FI120397 B FI 120397B FI 972628 A FI972628 A FI 972628A FI 972628 A FI972628 A FI 972628A FI 120397 B FI120397 B FI 120397B
- Authority
- FI
- Finland
- Prior art keywords
- methoxy
- pyridin
- phenoxy
- pyrimidin
- hydroxyethoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Bipolar Transistors (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Lubricants (AREA)
- Surgical Instruments (AREA)
Claims (10)
1. Föreningar med formeln (1} r2 R1S02MH R4 Rs y—(i R3 R8 R7 5 där R1 är fenyl eller fenyl, som är substituerad med halogen, Ci_7-alkyl, Ci_7-alkoxi, Ci_7-alkylendi-oxi, karboxyl eller trifluormetyl; eller hetero-cyklyl, som är mono- eller bicykliska, 5- och 6-10 ledade heterocykler, som har syre, kväve eller svavel som heteroatom; R2 är tetrazolyl, Ci-7-alkyl-substituerad tetrazo- lyl, cyan, karboxi, Ci-7-alkoxikarbonyl, hydroxi-metyl, formyl, karbamoyl, tiokarbamoyl, amidino 15 eller hydroxiamidino; R3 är en rest -0- (CRaRb)n~OR9; R4 - R8 är väte, Ci-7-alkoxi eller halogen; R9 är väte, bensyl, bensyl, som i fenylringen är substituerad med halogen, Ci_7-alkyl, Ci-7-alkoxi, 20 Ci-7-alkylendioxi, karboxyl eller trif luormetyl ; eller en rest -CiONHR10; R10 är Ci-7-alkyl, fenyl eller fenyl, som är substi tuerad med halogen, Ci-7-alkyl, Ci_7-alkoxi, Ci_7-alkylendioxi, karboxyl eller trifluormetyl; el-25 ler pyridyl eller pyridyl, som är substituerad med 1 eller 2 Ci-7-alkylgrupper; Ra och Rb är väte eller Ci_7-alkyl; n är 2, 3 eller 4; och A och B är CH; eller den ena av symbolerna A eller B är 30 kväve och den andra är CH; eller R2 är väte och den ena av symbolerna A eller B är N-oxid (N->0) och den andra är CH, och farma- ceutiskt användbara salter av föreningarna med formeln I.
2. Föreningar enligt patentkrav 1, känneteck-nade av att A och B är CH. 5
3. Föreningar enligt patentkrav 1, känneteck- nade av att den ena av symbolerna A eller B är kväve.
4. Föreningar enligt patentkrav 1, känneteck-n a d e av att den ena av symbolerna A är kväve och B är CH. 10
5. Föreningar enligt nagot av patentkraven 1-4, kännetecknade av att R2 är en tetrazolylrest.
6. Föreningar enligt nagot av patentkraven 1-5, kännetecknade av att R1 är fenyl- eller pyridylrest, som är monosubstituerad med Ci-7-alkyl, R3 är -0(CH2)nOH, -
15 O (CH2) n0-bensyl eller -O (CH2) nOC (O) NHR10 och n är 2.
7. Föreningar enligt nagot av patentkraven 1-6, kännetecknade av att R4 är Cx-7-alkoxi och R5 - R8 är väte; eller R2 är halogen, R7 är Cx-7-alkoxi och R5, R6 och R8 är väte. 20
8. Föreningar enligt nagot av patentkraven 1-7, 5-metyl-pyridin-2-sulfonsyra 6~(2-hydroxietoxi)-5-(2-metoxi-fenoxi}-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-py-rimidin-4-ylamid, 5-isopropyl-pyridin-2-sulfonsyra 6-(2-hydroxietoxi)- 25 5-(2-metoxi-fenoxi)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)- pyrimidin-4-ylamid, 4-tert-butyl-N-[6-(2-hydroxietoxi)-5-(2-metoxi-fen-oxi)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-bensensulfonamid, 30 2-[6-(4-tert-butyl-fenylsulfonylamino)-5-(2-met- oxi-fenoxi)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxi]-etyl pyridin-2-ylkarbamat, N-[6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-bensensulfon- 35 amid, N-[6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(2-1H-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4~yl]-4-metyl-ben-sensulfonamid, N-[6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(2-1H-5 tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-metoxi-ben-sensulfonamid, N-[6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(2 — 1H— tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-metylsulfa-nyl-bensensulfonamid, 10 1,3-bensodioxol-5-sulfonsyra 6-(2-hydroxietoxi)-5- (2-metoxi-fenoxi)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-py-rimidin-4-ylamid, N-[6~(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(2 — 1H— tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-3,4-dimetoxi-15 bensensulfonamid, N-[6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(2-1H-tetrazol-5-yl-pyridin~4-yl)-pyrimidin-4-yl]-2,5-dimetoxi-bensensulfonamid, pyridin-3-sulfonsyra 6-(2-hydroxietoxi)-5-(2-meto-20 xi-fenoxi)-2-(2-lH-tetrazol-5-yl~pyridin-4-yl)-pyrimidin- 4-ylamid, 4- tert-butyl-N-[5-(2-klor-5-metoxi-fenoxi)-6-(2-hydroxietoxi)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl)-bensensulfonamid, 25 1,3-bensodioxol-5-sulfonsyra [5-(2-klor-5-metoxi- fenoxi)-6-(2-hydroxietoxi)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-amid, 5- isopropyl-pyridin-2-sulfonsyra [5-(2-klor-5-met-oxi-fenoxi)-6-(2-hydroxietoxi)-2-(2-lH-tetrazol-5-yl-pyri- 30 din-4-yl)-pyrimidin-4-yl]-amid, 4-tert-butyl-N-[6-(2-hydroxietoxi)-5-(2-metoxi-fe-noxi)-2-[6-(lH-tetrazol-5-yl-pyridin-4-yl)]-pyrimidin-4-yl]-bensensulfonamid, 2-[5-(2-metoxi-fenoxi)-6-fenylsulfonylamino-2-(2-35 lH-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxi]-etylpy- ridin-2-ylkarbamat, 2-[5- (2-metoxi-fenoxi)-6-(4-metyl-fenylsulfonyl-amino)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxi]-etylpyridin-2-ylkarbamat, 2-[5-(2-metoxi-fenoxi)-6-(4-metyl-fenylsulfonyl-5 amino)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4- yloxi]-etyl 1,3-bensodioxol-5-ylkarbamat, 2-[5-(2-metoxi-fenoxi)-6-(4-metoxi-fenylsulfonyl-amino)-2-(2-lH-tetrazol-5-yl-pyridin-2-yl)-pyrimidin-4-yl-oxi]-etyl pyridin-2-ylkarbamat, 10 2-(5-(2-metoxi-fenoxi)-6-(4-metoxi-fenylsulfonyl- amino)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yloxi]-etyl 1,3-bensodioxol-5ylkarbamat, 2-[5-(2-metoxi-fenoxi)-6-(4-metylsulfanyl-fenyl-sulfonylamino)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimi-15 din-4-yloxi]-etyl pyridin-2-ylkarbamat, 2-[6-(1,3-bensdioxol-5-ylsulfonylamino)-5-(2-metoxi-fenoxi) -2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimidin- 4-yloxi]-etyl pyridin-2-ylkarbamat, 2-[6-(1,3-bensdioxol~5-ylsulfonylamino)-5-(2-meto-20 xi-fenoxi)-2-(2-lH-tetrazol~5~yl-pyridin-4-yl)-pyrimidin- 4-yloxi]-etyl 1,3-bensodioxol-5-ylkarbamat, 2-[6-(3,4-dimetoxi-fenylsulfonylamino)-5-(2-metoxi-fenoxi) -2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimidin- 4-yloxi]-etyl pyridin-2-ylkarbamat, 25 2-[5-(2-metoxi-fenoxi)-6-(2,5-dimetoxi-fenylsulfo- nylamino)-2-(2-lH-tetrazol-5-yl-pyrxdxn-4-yl)-pyrimidin-2-yloxi]-etyl pyridxn-2-ylkarbamat, 2-[5-(2-metoxi-fenoxi)-2-(2-lH-tetrazol-5-yl-pyri-din-4-yl)-6-pyridin-3-ylsulfonylamino-pyrimidin-4-yloxi]-30 etyl pyridin-2-ylkarbamat, 2-[5-(2-metoxi-fenoxi)-6-pyrxdin-3-ylsulfonylami-no-2-(2-lH-tetrazol-5-yl-pyrxdin-4-yl)-pyrimidin-4-yloxi]-etyl 1,3-bensodioxol-5-ylkarbamat, 2-[5-(2-metoxi-fenoxi)-6-(5-metyl-pyridin-2-ylsul-35 fonylamino)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimidin- 4-yloxi]-etyl pyrxdin-2-ylkarbamat, 2-[6-(5-isopropyl-pyridin-2-ylsulfonylamino)-5-(2-metoxi-fenoxi)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimi-din-4-yloxi]-etyl pyridin-2-ylkarbamat, 2-[6-(5-isopropyl-pyridin-2-ylsulfonylamino)-5-(2-5 metoxi-fenoxi)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyrimi- din-4-yloxi] -etyl 1,3-bensodioxol-5-ylkarbamat, 2-[6~(5-tert-butyl-fenylsulfonylamino)-5-(2-klor- 5-metoxi-fenoxi)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyri-midin-4-yloxi]-etyl pyridin-2-ylkarbamat, 10 2-[6-(1,3-bensodioxol-5-ylsulfonylamino)-5-(2-klor- 5-metoxi-fenoxi)-2-(2-lH-tetrazol-5-yl-pyridin-4-yl)-pyri-midin-4-yloxi]-etyl pyridin-2-ylkarbamat, 2-[5-(2-klor-5-metoxi-fenoxi)-6-(5-isopropyl-pyri-din-2-ylsulfonylamino]-2-(2-lH-tetrazol-5-yl-pyridin-2-yl)-15 pyrimidin-4-yloxi]-etyl pyridin-2-ylkarbamat, 2-[6-{4-tert-butyl-fenylsulfonylamino)-5-(2-metoxi-fenoxi) -2-(2-lH-tetrazol-5-yl-pyridin-2-yl)-pyrimidin- 4-yloxi]-etyl pyridin-2-ylkarbamat, N-(6-(2-bensyloxi-etoxi)-5-(2-metoxi-fenoxi)-2-(2-20 lH-tetrazol-5-yl-pyridin-4-yl)-pyrimidin-4-yl]-4-tert-bu- tyl-bensensulfonamid, 5-metyl-pyridin-2-sulfonsyra [6- (2-bensyloxi-eto-xi)-5-(2-metoxi-fenoxi)-2-(2-lH-tetrazol~5~yl~pyridin~4~ yl)]-amid, 25 5-isopropyl-pyridin-2-sulfonsyra [6-(2-bensyloxi- etoxi) -5-(2-metoxi-fenoxi)-2-[2-(lH-tetrazol-5-yl-pyridin- 4-yl)]-pyrimidin-4-yl]-amid, 4-tert-butyl-N-(2-[2-(l-etyl-lH-tetrazol-5-yl)py-ridin-4-yl]-6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-pyrimi-30 din-4-yl]-bensensulfonamid, 4-tert-butyl-N-(2-(3-cyan-fenyl)-6-(2-hydroxietoxi) -5-(2-metoxi-fenoxi)-pyrimidin-4-yl]-bensensulfonamid, 4-tert-butyl-N-(6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi) -2-(3~lH~tetrazol-5-yl-fenyl)-pyrimidin-4-yl]-ben-35 sensulfonamid, 2-[6-(4-tert-butyl-fenylsulfonylamino)-5-(2-meto-xi-fenoxi) -2- (3-lH-tetrazol-5-yl-fenyl) -pyrimidin-4-yloxi] -etyl pyridin-2-ylkarbamat, N- [ 6- (2-bensyloxi-etoxi)-2-(3-cyan-fenyl)-5-(2-me-5 toxi-fenoxi)-pyrimidin-4-yl]-4-tert-butyl-bensensulfonamid, N-[6-(2-bensyloxi-etoxi)-5-(2~metoxi-fenoxi)-2- (3-lH-tetrazol-5-yl-fenyl)-pyrimidin-4-yl]-4-tert-butyl-ben-sensulfonamid, 4-tert-butyl-N-[2-(4-cyan-fenyl)-6-(2-hydroxieto-10 xi)-5-(2-metoxi-fenoxi)-pyrimidin-4-yl)-bensensulfonamid, 4-tert-butyl-N-[6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(4-lH-tetrazol-5-yl-fenyl)-pyrimidin-4-yl]-bensensulfonamid, N-[6- (2-bensyloxi-etoxi)-2-(4-cyan-fenyl)-5-(2-15 metoxi-fenoxi)-pyrimidin-4-yl]-4-tert-butyl-bensensulfon- amid, N-[6-(2-bensyloxi-etoxi)-5-(2-metoxi-fenoxi)-2-(4-lH-tetrazol-5-yl-fenyl)-pyrimidin-4-yl]-4-tert-butyl-ben-sensulfonamid, 20 4-tert-butyl-N-[2-(2-cyan-pyridin-4-yl)-6-(2-hyd roxietoxi) -5- (2-metoxi-fenoxi) -pyrimidin-4-yl] -bensensulfonamid, N-[2- (2-cyan-pyridin-4-yl)-6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-pyrimidin-4-yl]-bensensulfonamid,
25 N-[2-(2-cyan-pyridin-4-yl)-6-(2-hydroxietoxi)-5- (2-metoxi-fenoxi)-pyrimidin-4-yl]-4-metyl-bensensulfon-amid, N-(2-(2-cyan-pyridin-4-yl)-6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-pyrimidin-4-yl]-4-metoxi-bensensulfon-30 amid, N-[2-(2-cyan-pyridin-4-yl)-6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-pyrimidin-4-yl]-4-metylsulfanyl-bensen-sulfonamid, 1,3-bensodioxol-5-sulfonsyra 2-(2-cyan-pyridin-4-35 yl)-6- (2-hydroxietoxi)-5-(2-metoxi-fenoxi)-pyrimidin-4- ylamid, N-[2-(2-cyan-pyridin-4-yl}-6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-pyrimidin-4-yl]-3,4-dimetoxi-bensensul-fonamid, N-[2-(2-cyan-pyridin-4~yl)-6-(2-hydroxietoxi)-5-5 (2-metoxi-fenoxi)-pyrimidin-4-yl]-2,5-dimetoxi-bensensul- fonamid, pyridin-3-sulfonsyra 2-(2-cyan-pyridin~4~yl) -6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-pyrimidin-4-ylamid, 5-metyl-pyridin-2-sulfonsyra 2-(2-cyan-pyridin-4-10 yl) -6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-pyrimidin-4-yl- amid, 5-isopropyl-pyridin-2-sulfonsyra 2-(2-cyan-pyridin-4 —yl)-6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-pyrimidin-4-ylamid, 15 4-tert-butyl-N-[5-(2-klor-5-metoxi-fenoxi)-2-(2- cyan-pyridin-4-yl)-6-(2-hydroxietoxi)-pyrimidin-4-yl]-ben-sensulfonamid, 1,3-bensodioxol~5-sulfonsyra 5- (2-klor-5-metoxi-fe-noxi)-2-(2-cyan-pyridin-4-yl)-6-(2-hydroxietoxi)-pyrimi-20 din-4-ylamid, 5-isopropyl-pyridin-2"Sulfonsyra 5-(2-klor-5-meto-xi-fenoxi)-2-(2-cyan-pyridin-4-yl)-6-(2-hydroxietoxi)-py-rimidin-4-ylamid, 4-tert-butyl-N-[2-(6-cyan-pyridin-2-yl)-6-(2-hyd-25 roxietoxi)-5-(2-metoxi-fenoxi)-pyrimidin-4-yl]-bensensul- fonamid, N-[6- (2-bensyloxi-etoxi)-2-(2-cyan-pyrdin-4-yl)-5-(2-metoxi-fenoxi)-pyrimidin-4-yl]-4-tert-butyl-bensensul-fonamid, 30 5-isopropyl-pyridin-2-sulfonsyra-N-[6-(2-bensyl- oxi-etoxi)-2-(2-cyan-pyrdin-4-yl)-5-(2-metoxi-fenoxi)-pyrimidin-4-yl]-amid, 4-tert-butyl-N-[2-[2-(amino-imino-metyl)-pyridin- 4-yl]-6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-pyrimidin-4-35 yl]-bensensulfonamid, 4- tert-butyl-N-[2-[2-(hydroxiamino-imino-metyl) -pyridin-4-yl]-6-(2-hydroxietoxi)-5-{2-metoxi-fenoxi)-pyri-midin-4~yl] -bensensulfonamid, etyl N- [4- (4-tert-butyl-fenylsulfonylamino)-6-(2-5 hydroxietoxi)-5-(2-metoxi-fenoxi)-pyrimidin-2-yl]-pyridin- 2-karboxylat, N-[4-(4-tert-butyl-fenylsulfonylamino)-6-(2-hydroxietoxi) -5-(2-metoxi-fenoxi)-pyrimidin-2-yl]-pyridin-2-karboxylsyra,
10 N-[4-(4-tert-butyl-fenylsulfonylamino)-6-(2-hydro xietoxi )-5-(2-metoxi-fenoxi)-pyrimidin-2-yl]-pyridin 1-oxid, N-[6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2- (1-oxi-pyridin-4-yl)-pyrimidin-4-yl]-bensensulfonamid, N-[6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(1-oxi-15 pyridin-4-yl)-pyrimidin-4-yl]-4-metyl-bensensulfonamid, N-[6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(1-oxi-pyridin-4-yl)-pyrimidin-4-yl]-4-metoxi-bensensulfonamid, N-[6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(1-oxi-pyridin-4-yl)-pyrimidin-4-yl]-4-metylsulfanyl-20 bensensulfonamid, 1,3-bensidioxol-5-sulfonsyra 6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(l-oxi-pyridin-4-yl)-pyrimidin-4-yl-amid, N-[6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(1-oxi-25 pyridin-4-yl)-pyrimidin-4-yl]-3,4-dimetoxi-bensensulfon amid, N-[6- (2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(1-oxi-pyridin-4-yl)-pyrimidin-4-yl]-2,5-dimetoxi-bensensulfon-amid, 30 pyridin-3-sulfonsyra 6- (2-hydroxietoxi)-5-(2-meto- xi-fenoxi)-2-(l-oxi-pyridin-4-yl)-pyrimidin-4-yl-amid, 5- metyl-pyridin-2-sulfonsyra 6-(2-hydroxietoxi)-5-(2-metoxi-fenoxi)-2-(l-oxi-pyridin-4-yl)-pyrimidin-4-yl-amid, 5-isopropyl-pyridin-2-sulfonsyra 6-(2-hydroxieto-xi)-5-(2-metoxi-fenoxi)-2-(l-oxi-pyridin-4-yl)-pyrimidin-4-yl-amid, 4-tert-butyl-N-[5-(2~klor-5-metoxi-fenoxi)-6-(2-5 hydroxietoxi)-2-(l-oxi-pyridin-4-yl)-pyrimidin-4-yl]-ben-sensulfonamid, 1,3-bensodioxol-4-sulfonsyra 5-(2-klor-5-metoxi~ fenoxi)-6-(2-hydroxietoxi)-2-{l-oxi-pyridin~4-yl)-pyrimi-din-4-ylamid, 10 5~isopropyl-pyridin-4“Sulfonsyra 5-(2-klor-5-meto- xi-fenoxi)-6-(2-hydroxietoxi)-2-(l-oxi-pyridin-4-yl)-pyri-midin-4-ylamid, 2-[4~(4-tert-butyl-fenylsulfonylamino)-6-(2-hydroxietoxi) -5-(2-metoxi-fenoxi}-pyrimidin-2-yl]-pyridin 1-oxid. 15
9. Farmaceutiska preparat, speciellt sädana, som är avsedda för att behandla störningar, som hänför sig till endotelinaktiviteter, speciellt blodcirkulationsstör-ningar, sasom hypertension, ischemi, vasospasm och angina pectoris, kännetecknade av att de innehäller en fö-20 rening enligt nagot av patentkraven 1-8 och konventio-nella bärarmaterial och adjuvanter.
10. Användning av föreningar enligt nagot av patentkraven 1-8 som aktiva ingredienter vid framställning av rnedikament, som är avsedda för att behandla störningar, 25 som hänför sig till endotelinaktiviteter, speciellt blod-cirkulationsstörningar, sasom hypertension, ischemi, vasospasm och angina pectoris.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH383794 | 1994-12-20 | ||
CH383794 | 1994-12-20 | ||
CH241995 | 1995-08-24 | ||
CH241995 | 1995-08-24 | ||
PCT/EP1995/004843 WO1996019459A1 (en) | 1994-12-20 | 1995-12-08 | Novel sulfonamides |
EP9504843 | 1995-12-08 |
Publications (3)
Publication Number | Publication Date |
---|---|
FI972628A0 FI972628A0 (sv) | 1997-06-18 |
FI972628A FI972628A (sv) | 1997-06-18 |
FI120397B true FI120397B (sv) | 2009-10-15 |
Family
ID=25690401
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI972628A FI120397B (sv) | 1994-12-20 | 1997-06-18 | Nya sulfonamider |
Country Status (26)
Country | Link |
---|---|
US (1) | US6004965A (sv) |
EP (1) | EP0799209B1 (sv) |
JP (1) | JP2989014B2 (sv) |
KR (1) | KR100445085B1 (sv) |
CN (1) | CN1098254C (sv) |
AT (1) | ATE246681T1 (sv) |
AU (1) | AU701767B2 (sv) |
BR (1) | BR9510104A (sv) |
CA (1) | CA2208018C (sv) |
CY (1) | CY2495B1 (sv) |
CZ (1) | CZ287916B6 (sv) |
DE (1) | DE69531457T2 (sv) |
DK (1) | DK0799209T3 (sv) |
ES (1) | ES2203649T3 (sv) |
FI (1) | FI120397B (sv) |
HK (1) | HK1001973A1 (sv) |
HU (1) | HU228619B1 (sv) |
IL (1) | IL116385A (sv) |
MA (1) | MA23744A1 (sv) |
MY (1) | MY131126A (sv) |
NO (1) | NO316645B1 (sv) |
NZ (1) | NZ297797A (sv) |
PT (1) | PT799209E (sv) |
SA (1) | SA95160421B1 (sv) |
TW (1) | TW313568B (sv) |
WO (1) | WO1996019459A1 (sv) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6063911A (en) * | 1993-12-01 | 2000-05-16 | Marine Polymer Technologies, Inc. | Methods and compositions for treatment of cell proliferative disorders |
TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
EP2002846B1 (en) | 1996-12-06 | 2017-01-25 | Amgen Inc. | Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases |
DE69824090T2 (de) * | 1997-08-19 | 2005-07-07 | F. Hoffmann-La Roche Ag | Verfahren zur Herstellung von 2,5-disubstituierter Pyridine |
US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
ATE311382T1 (de) * | 1998-08-10 | 2005-12-15 | Verfahren zur herstellung von 2-carbamoyl- pyridinen | |
ATE556713T1 (de) | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
EP1140840B1 (en) * | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
ME00275B (me) | 1999-01-13 | 2011-02-10 | Bayer Corp | ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE |
TWI284642B (en) | 1999-01-18 | 2007-08-01 | Hoffmann La Roche | Novel heterocyclic sulfonamides |
US6417360B1 (en) * | 1999-03-03 | 2002-07-09 | Hoffmann-La Roche Inc. | Heterocyclic sulfonamides |
ZA200002318B (en) * | 1999-05-22 | 2000-11-16 | Actelion Pharmaceuticals Ltd | Aqueous pharmaceutical composition. |
AU747596B2 (en) * | 1999-05-22 | 2002-05-16 | Actelion Pharmaceuticals Ltd | Aqueous pharmaceutical composition |
CA2315614C (en) | 1999-07-29 | 2004-11-02 | Pfizer Inc. | Pyrazoles |
CA2361402C (en) * | 1999-09-03 | 2009-05-12 | Actelion Pharmaceuticals Ltd | Bis-sulfonamides |
CN1407973A (zh) * | 1999-12-22 | 2003-04-02 | 埃科特莱茵药品有限公司 | 丁炔二醇衍生物 |
AU2001265871A1 (en) * | 2000-04-25 | 2001-11-07 | Actelion Pharmaceuticals Ltd | Substituted sulfonylaminopyrimidines |
US6387915B2 (en) | 2000-05-31 | 2002-05-14 | Pfizer Inc. | Isoxazole-sulfonamide endothelin antagonists |
US6670362B2 (en) | 2000-09-20 | 2003-12-30 | Pfizer Inc. | Pyridazine endothelin antagonists |
US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
DE60118782T2 (de) * | 2000-12-18 | 2007-01-25 | Actelion Pharmaceuticals Ltd. | Neue sulfamiden und deren verwendung als endothelin-antagonisten |
US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
WO2002083650A1 (en) * | 2001-04-11 | 2002-10-24 | Actelion Pharmaceuticals Ltd | Novel sulfonylamino-pyrimidines |
US7371763B2 (en) | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
AU2003209116A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
WO2003068746A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Aryl ureas as kinase inhibitors |
WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
US20040002451A1 (en) | 2002-06-20 | 2004-01-01 | Bruce Kerwin | Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing |
ATE423103T1 (de) * | 2002-12-02 | 2009-03-15 | Actelion Pharmaceuticals Ltd | Pyrimidin-sulfonamide und ihre verwendung als endothelin-rezeptor-antagonisten |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
PT1636585E (pt) | 2003-05-20 | 2008-03-27 | Bayer Pharmaceuticals Corp | Diarilureias com actividade inibidora de cinase |
JP4777887B2 (ja) | 2003-07-23 | 2011-09-21 | バイエル、ファーマシューテイカルズ、コーポレイション | 病気および状態の処置および防止のためのフロロ置換オメガカルボキシアリールジフェニル尿素 |
GB0327839D0 (en) | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
KR20070006774A (ko) | 2004-03-17 | 2007-01-11 | 노파르티스 아게 | 치료에서 레닌 억제제의 용도 |
TW200628467A (en) | 2004-11-11 | 2006-08-16 | Actelion Pharmaceuticals Ltd | Novel sulfamides |
US7402730B1 (en) | 2005-02-03 | 2008-07-22 | Lexicon Pharmaceuticals, Inc. | Knockout animals manifesting hyperlipidemia |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
MX2009000646A (es) | 2006-07-20 | 2009-01-29 | Novartis Ag | Derivados de amino-piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp). |
AR062501A1 (es) | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
ZA200904022B (en) | 2006-12-08 | 2010-08-25 | Lexicon Pharmaceuticals Inc | Monoclonal antibodies against ANGPTL3 |
NZ599605A (en) | 2007-02-19 | 2013-11-29 | Marinepolymer Tech Inc | Hemostatic compositions and therapeutic regimens |
MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
FR2921062A1 (fr) | 2007-09-17 | 2009-03-20 | Commissariat Energie Atomique | Composes utiles comme ligands et notamment comme chromophores organiques de complexation des lanthanides et leurs applications |
EP2207775B1 (en) | 2007-11-05 | 2012-03-21 | Novartis AG | 4-benzylamino-1-carboxyacyl-piperidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis |
EP2229356B1 (en) | 2007-12-03 | 2011-10-12 | Novartis AG | 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis |
CN102459247B (zh) | 2009-05-15 | 2014-09-17 | 诺华股份有限公司 | 作为醛固酮合酶抑制剂的苯并噁唑酮衍生物 |
JP5659224B2 (ja) | 2009-05-15 | 2015-01-28 | ノバルティス アーゲー | アルドステロンシンターゼ阻害剤としてのアリールピリジン |
SG176010A1 (en) | 2009-05-28 | 2011-12-29 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
AU2010251967B9 (en) | 2009-05-28 | 2014-04-03 | Novartis Ag | Substituted aminopropionic derivatives as neprilysin inhibitors |
ES2663351T3 (es) | 2009-11-17 | 2018-04-12 | Novartis Ag | Derivados de aril-piridina como inhibidores de la aldosterona sintasa |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
JP5575913B2 (ja) | 2009-11-30 | 2014-08-20 | ノバルティス アーゲー | アルドステロン合成酵素阻害剤としてのイミダゾール誘導体 |
BR112012025844A2 (pt) | 2010-04-15 | 2017-07-18 | Marine Polymer Tech Inc | uso de nanofibras snag |
US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
RU2013123793A (ru) | 2010-11-24 | 2014-12-27 | Лексикон Фармасьютикалз, Инк. | Антитела, связывающиеся с notum пектинацетилэстеразой |
ES2712098T3 (es) | 2011-04-15 | 2019-05-09 | Marine Polymer Tech Inc | Tratamiento de infecciones por VHS con nanofibras de poli-N-acetilglucosamina |
UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
US9383357B2 (en) | 2012-12-07 | 2016-07-05 | Northwestern University | Biomarker for replicative senescence |
JP6295277B2 (ja) | 2013-02-14 | 2018-03-14 | ノバルティス アーゲー | Nep(中性エンドペプチダーゼ)阻害剤としての置換ビスフェニルブタン酸ホスホン酸誘導体 |
KR20160031551A (ko) | 2013-07-25 | 2016-03-22 | 노파르티스 아게 | 심부전의 치료를 위한 시클릭 폴리펩티드 |
AU2014293387B2 (en) | 2013-07-25 | 2017-04-20 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
EA201791668A1 (ru) | 2015-01-23 | 2017-11-30 | Новартис Аг | Синтетические конъюгаты апелина с жирной кислотой с улучшенным периодом полураспада |
UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
TWI835843B (zh) | 2018-10-03 | 2024-03-21 | 瑞士商亨斯邁紡織染化(瑞士)有限公司 | 新的經吡啶及經嘧啶取代之三uv吸收劑 |
KR20230104232A (ko) | 2020-11-05 | 2023-07-07 | 이도르시아 파마슈티컬스 리미티드 | 클라조센탄 디소듐 염의 안정한 결정성 수화물 |
WO2023111299A1 (en) | 2021-12-17 | 2023-06-22 | Idorsia Pharmaceuticals Ltd | Clazosentan disodium salt, its preparation and pharmaceutical compositions comprising the same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW270116B (sv) * | 1991-04-25 | 1996-02-11 | Hoffmann La Roche | |
RU2086544C1 (ru) * | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
TW287160B (sv) * | 1992-12-10 | 1996-10-01 | Hoffmann La Roche | |
TW394761B (en) * | 1993-06-28 | 2000-06-21 | Hoffmann La Roche | Novel Sulfonylamino Pyrimidines |
IL111959A (en) * | 1993-12-17 | 2000-07-16 | Tanabe Seiyaku Co | N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them |
-
1995
- 1995-11-11 TW TW084111957A patent/TW313568B/zh not_active IP Right Cessation
- 1995-11-29 SA SA95160421A patent/SA95160421B1/ar unknown
- 1995-12-08 WO PCT/EP1995/004843 patent/WO1996019459A1/en active IP Right Grant
- 1995-12-08 US US08/860,107 patent/US6004965A/en not_active Expired - Lifetime
- 1995-12-08 DE DE69531457T patent/DE69531457T2/de not_active Expired - Lifetime
- 1995-12-08 AT AT95941706T patent/ATE246681T1/de active
- 1995-12-08 NZ NZ297797A patent/NZ297797A/en not_active IP Right Cessation
- 1995-12-08 ES ES95941706T patent/ES2203649T3/es not_active Expired - Lifetime
- 1995-12-08 DK DK95941706T patent/DK0799209T3/da active
- 1995-12-08 PT PT95941706T patent/PT799209E/pt unknown
- 1995-12-08 KR KR1019970704135A patent/KR100445085B1/ko not_active IP Right Cessation
- 1995-12-08 CA CA002208018A patent/CA2208018C/en not_active Expired - Lifetime
- 1995-12-08 EP EP95941706A patent/EP0799209B1/en not_active Expired - Lifetime
- 1995-12-08 CN CN95196948A patent/CN1098254C/zh not_active Expired - Lifetime
- 1995-12-08 JP JP8519469A patent/JP2989014B2/ja not_active Expired - Lifetime
- 1995-12-08 BR BR9510104A patent/BR9510104A/pt not_active IP Right Cessation
- 1995-12-08 HU HU9702407A patent/HU228619B1/hu unknown
- 1995-12-08 CZ CZ19971874A patent/CZ287916B6/cs not_active IP Right Cessation
- 1995-12-08 AU AU43041/96A patent/AU701767B2/en not_active Expired
- 1995-12-14 IL IL11638595A patent/IL116385A/xx not_active IP Right Cessation
- 1995-12-15 MA MA24095A patent/MA23744A1/fr unknown
- 1995-12-18 MY MYPI95003923A patent/MY131126A/en unknown
-
1997
- 1997-06-04 NO NO19972538A patent/NO316645B1/no not_active IP Right Cessation
- 1997-06-18 FI FI972628A patent/FI120397B/sv not_active IP Right Cessation
-
1998
- 1998-02-09 HK HK98100968A patent/HK1001973A1/xx not_active IP Right Cessation
-
2004
- 2004-12-14 CY CY0400089A patent/CY2495B1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI120397B (sv) | Nya sulfonamider | |
FI112944B (sv) | Förfarande för framställning av nya terapeutiskt användbara sulfonylaminopyrimidinderivat | |
KR100819668B1 (ko) | 신규한 피리미딘-설퍼아마이드 | |
AU2663000A (en) | 4-(heterocyclylsulfonamido) -5-methoxy-6- (2-methoxyphenoxy) -2-phenyl- or pyridylpyrimidines as endothelin receptor antagonists | |
WO2001017976A1 (en) | Bis-sulfonamides | |
US7091201B2 (en) | Arylalkane-sulfonamides having endothelin-antagonist activity | |
FI117896B (sv) | Nya sulfonamider | |
AU2002212171A1 (en) | Arylalkane-sulfonamides having endothelin-antagonist activity | |
WO2001081335A1 (en) | Pyrimidine-sulfonamides having endothelin-antagonist activity | |
PL185692B1 (pl) | Nowe sulfonamidy, sposób ich wytwarzania oraz zawierające je preparaty farmaceutyczne | |
RU2151767C1 (ru) | Сульфонамиды и фармацевтическая композиция | |
NO327220B1 (no) | Alkansulfonamider, fremgangsmate for fremstilling av slike, disse forbindelsene for anvendelse som medikamenter for behandling av lidelser samt anvendelse for fremstilling av medikamenter for behandling av lidelser | |
WO2002083650A1 (en) | Novel sulfonylamino-pyrimidines | |
MXPA97004587A (es) | Sulfonamidas novedosas | |
EP1322624B1 (en) | Arylalkane-sulfonamides having endothelin-antagonist activity | |
RU2173317C2 (ru) | Сульфонамидные производные и фармацевтический препарат | |
KR100521950B1 (ko) | 설포닐아미노피리미딘 | |
JP2002138083A (ja) | ビススルホンアミド |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Patent granted |
Ref document number: 120397 Country of ref document: FI |
|
MA | Patent expired |